CANDEL THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
CANDEL THERAPEUTICS INC. - More news...
CANDEL THERAPEUTICS INC. - More news...
- Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Candel Therapeutics Announces Pricing of Public Offering
- Candel Therapeutics Announces $80 Million Proposed Public Offering
- Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
- Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
- Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
- Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
- Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Candel Therapeutics to Join Russell 3000® Index
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
- Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
- Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
- Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
- Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
- CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
- Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
- Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
- Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
- Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
